Excellent start to 2017 for YProtech

YProtech, the synthetic chemistry company providing specialist services to the pharmaceutical, life sciences and applied chemical sectors has had a good start to 2017.

Since the beginning of the year, YProtech have secured new business of £0.6 million which will see them operating at full capacity until the end of August 2017.

Since receiving further investment in October 2016, YProtech has completed the installation and commissioned the new high potency facility.

YProtech recruited a new chemist in November 2016 and have just agreed the recruitment of three additional chemists to begin in April 2017 to enable the delivery of various current projects while also providing resource for any additional business to be secured in the future.

YProtech exhibited at the 7th World ADC Berlin event in February to globally launch their high potency expertise and capabilities. The exhibition has generated significant interest from key Biotech and Pharma companies in the ADC sector and follow up discussions over the coming weeks and months will drive the high potency pipeline.

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.